Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
78 participants
INTERVENTIONAL
2015-09-03
2016-01-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Evaluation of Etafilcon A Contact Lenses Using a Novel Manufacturing Technology
NCT03962790
Clinical Evaluation of Investigational Contact Lenses
NCT02801396
Daily Disposable Comparison Study
NCT02094677
Clinical Evaluation of Daily Disposable Etafilcon A Cosmetic Contact Lenses
NCT04529109
The Effect of Masking on Subjective Results During Daily Disposable Contact Lens Studies
NCT01155726
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lens 1/ Lens 2/ Lens 3
Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (nesofilcon A) third.
Lens 1 (etafilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 2 (nelfilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 3 (nesofilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 1 / Lens 3 / Lens 2
Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 2 (nelfilcon A) third.
Lens 1 (etafilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 2 (nelfilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 3 (nesofilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 2/ Lens 3/ Lens 1
Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 1 (etafilcon A) third .
Lens 1 (etafilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 2 (nelfilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 3 (nesofilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 2 / Lens 1/ Lens 3
Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nesofilcon A) third. Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 1 (etafilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 2 (nelfilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 3 (nesofilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 3 / Lens 1 / Lens 2
Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nelfilcon A) third.
Lens 1 (etafilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 2 (nelfilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 3 (nesofilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 3 / Lens 2 / Lens 1
Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (etafilcon A) third.
Lens 1 (etafilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 2 (nelfilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 3 (nesofilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lens 1 (etafilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 2 (nelfilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Lens 3 (nesofilcon A)
Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol;
* The subject must be willing and able to follow instructions and maintain the appointment schedule;
* The subject must be between the age of 18 and 40 years (inclusive);
* The subject's vertex corrected spherical equivalent distance refraction must be in the range of -0.50 Diopters (D) to -6.00 D in each eye (inclusive);
* The subject's refractive cylinder must not exceed -1.25 Diopters of Cylinder (DC) in each eye after vertexing to the corneal plane;
* The subject must have best corrected visual acuity of 0.2 Logarithm of the Minimum Angle of Resolution (logMAR) or better in each eye;
* The subject must be a current wearer of spherical, soft contact lenses (no toric, bifocal or multifocal contact lenses, no extended wear or monovision) for at least 5 days/week and at least 8 hours/day during the month prior to enrollment;
* The subject must own a wearable pair of spectacles and wear them the day of the initial visit;
* The subject must be an existing wearer of spherical, soft contact lenses in both eyes;
* The subject must have normal eyes (i.e., no ocular medications or infections of any type);
* The subject must be willing to wear the study lenses for a minimum eight hours per day.
Exclusion Criteria
* Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear (at the investigator's discretion);
* Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued);
* Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease;
* Any active ocular infection;
* Is using any topical medications (excluding artificial tears (ATS)) up to two weeks prior to the screening visit;
* Any participants whose habitual contact lenses are used as an extended wear regimen;
* Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion by keratometry;
* Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy, photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK), etc.);
* Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear; or clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which might interfere with contact lens wear;
* Any known hypersensitivity or allergic reaction to the study products;
* Participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment;
* Employee or family member of the Centre for Contact Lens Research (e.g., Investigator, Coordinator, Technician).
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johnson & Johnson Vision Care, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre for Contact Lens Research
Waterloo, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CR-5735
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.